News Tocagen’s brain tumour candidate gets PRIME designation An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.
News Immunotherapy for brain cancer gets European PRIME status Latest addition to EMA's fast-track for cutting edge drugs
Articles Europe launches new PRIME fast-track for promising medicines Andrew McConaghie reports on a newly-launched plan to speed up access to groundbreaking new medicines in Europe.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
